Phenytoin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Phenytoin: From Epilepsy to Audiogenic Seizures
One-Sentence Summary
Phenytoin is a voltage-gated sodium channel blocker originally used to control generalized tonic-clonic and partial seizures in epilepsy. The TxGNN model predicts it may also be effective for Audiogenic Seizures (a reflex epilepsy subtype triggered by sound), with 0 clinical trials but 19 supporting publications (mostly preclinical/animal pharmacology studies plus one clinical case report) currently backing this direction.
Note on candidate selection: TxGNN’s top-ranked prediction (“trigeminal nerve neoplasm”) was excluded from this report. The evidence pack itself flags it as a likely knowledge-graph artifact — a probable confusion between “trigeminal neuralgia” and “trigeminal nerve neoplasm” — with no mechanistic, trial, or literature support (Evidence Level L5, recommendation Hold). Among the remaining candidates, audiogenic seizures has by far the strongest and most direct body of evidence, so it is presented here instead.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy (generalized tonic-clonic and partial seizures) — not present in the structured taiwan_regulatory data, based on well-established pharmacology referenced throughout the evidence pack |
| Predicted New Indication | Audiogenic Seizures |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 (preclinical/mechanistic studies) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for phenytoin was not returned from DrugBank in this evidence pack (original_moa: [Data Gap]). However, the repurposing rationale fields consistently identify phenytoin as a voltage-gated sodium channel blocker, the same mechanism underlying its established anticonvulsant effect in epilepsy.
Audiogenic seizures are a reflex epilepsy subtype in which sound stimuli trigger abnormal, excessive cortical and subcortical (periaqueductal gray / pontine reticular formation) electrical activity. Because phenytoin’s sodium-channel-blocking action raises the seizure threshold broadly, rather than acting on a disease-specific target, it is mechanistically plausible that this effect extends to reflex seizure subtypes such as audiogenic seizures — not just to spontaneous epilepsy.
This is not purely theoretical: multiple animal-model studies (e.g. PMID 10719079, 12948620, 7211184) directly test phenytoin’s anticonvulsant activity against audiogenic seizures in genetically epilepsy-prone rodents (GEPR, DBA/2 mice), and a human case report (PMID 21561835) describes phenytoin used successfully for a different reflex seizure subtype (micturition/defecation-induced seizures), supporting cross-subtype extrapolation of phenytoin’s efficacy within the broader reflex epilepsy category.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21561835 | 2011 | Case Report | Epileptic Disorders | Reflex seizures induced by micturition and defecation successfully treated with clobazam and phenytoin — clinical evidence of phenytoin efficacy in a related reflex-epilepsy subtype |
| 10719079 | 2000 | Animal Study | Brain Research | Phenytoin administration alters pontine reticular formation and periaqueductal gray neuronal firing in genetically epilepsy-prone rats, directly linked to suppression of audiogenic seizure behavior |
| 12948620 | 2003 | Animal Study | Epilepsy Research | A static magnetic field modulates audiogenic seizure severity and the anticonvulsant effects of phenytoin in DBA/2 mice |
| 7211184 | 1981 | Animal Study | Acta Neurologica Scandinavica | Withdrawal from long-term phenytoin (diphenylhydantoin) treatment increases susceptibility to audiogenic and electroshock-induced seizures in rats |
| 9592113 | 1998 | Animal Study | J Neuroscience | Magnesium-deficiency-dependent audiogenic seizure model used for discriminatory anticonvulsant drug screening |
| 22107891 | 2012 | Animal Study | Pharmacological Research | ACE inhibitors potentiate the anticonvulsant activity of antiepileptic drugs, including phenytoin, against audiogenic seizures in DBA/2 mice |
| 27663280 | 2016 | Animal Study | European J Pharmacology | Cannabinoid receptor agonists modulate the anticonvulsant activity of AEDs, including phenytoin, against audiogenic seizures in DBA/2 mice |
| 11284448 | 2001 | Animal Study | Naunyn-Schmiedeberg’s Arch Pharmacol | Retigabine potentiates the anticonvulsant activity of AEDs, including phenytoin, against audiogenic seizures in DBA/2 mice |
| 10863138 | 2000 | Animal Study | Epilepsy Research | D-cycloserine potentiates the anticonvulsant activity of AEDs, including phenytoin, against audiogenic seizures in DBA/2 mice |
| 3418335 | 1988 | Animal Study | J Neural Transmission | Clinical, pharmacological, and EEG characterization of the audiogenic seizure model in Wistar rats, foundational to subsequent anticonvulsant screening studies |
South Africa Market Information
Phenytoin has no SAHPRA registrations recorded in this evidence pack (total_licenses: 0, market status: Not Marketed). No product-level registration or Essential Medicines List data is available to report.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence for audiogenic seizures is currently limited to animal pharmacology studies (L4) plus one human case report for a different reflex-epilepsy subtype; there are no clinical trials, and phenytoin has no current SAHPRA registration in South Africa, so there is no regulatory pathway to act on immediately.
To proceed, the following is needed:
- TFDA/SAHPRA-equivalent professional information (warnings, contraindications) — currently a blocking data gap (DG001)
- Formal DrugBank-sourced mechanism-of-action data (DG002)
- A feasibility assessment for a Phase 1/2 proof-of-concept trial in audiogenic or other reflex epilepsy subtypes
- Confirmation of any existing SAHPRA registration pathway, since phenytoin is currently not marketed in South Africa under this dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.